Are intersectoral costs considered in economic evaluations of interventions relating to sexually transmitted infections (STIs)? A systematic review.

Lena Schnitzler, Silvia M A A Evers, Louise J Jackson, Aggie T G Paulus, Tracy E Roberts
Author Information
  1. Lena Schnitzler: Health Economics Unit, Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
  2. Silvia M A A Evers: Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Faculty of Health, Medicine and Life Sciences (FHML), Maastricht University, Maastricht, The Netherlands.
  3. Louise J Jackson: Health Economics Unit, Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. l.jackson.1@bham.ac.uk.
  4. Aggie T G Paulus: Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Faculty of Health, Medicine and Life Sciences (FHML), Maastricht University, Maastricht, The Netherlands.
  5. Tracy E Roberts: Health Economics Unit, Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.

Abstract

BACKGROUND/OBJECTIVE: Sexually transmitted infections (STIs) not only have an impact on the health sector but also the private resources of those affected, their families and other sectors of society (i.e. labour, education). This study aimed to i) review and identify economic evaluations of interventions relating to STIs, which aimed to include a societal perspective; ii) analyse the intersectoral costs (i.e. costs broader than healthcare) included; iii) categorise these costs by sector; and iv) assess the impact of intersectoral costs on the overall study results.
METHODS: Seven databases were searched: MEDLINE (PubMed), EMBASE (Ovid), Web of Science, CINAHL, PsycINFO, EconLit and NHS EED. Key search terms included terms for economic evaluation, STIs and specific infections. This review considered trial- and model-based economic evaluations conducted in an OECD member country. Studies were included that assessed intersectoral costs. Intersectoral costs were extracted and categorised by sector using Drummond's cost classification scheme (i.e. patient/family, productivity, costs in other sectors). A narrative synthesis was performed.
RESULTS: Twenty-nine studies qualified for data extraction and narrative synthesis. Twenty-eight studies applied a societal perspective of which 8 additionally adopted a healthcare or payer perspective, or both. One study used a modified payer perspective. The following sectors were identified: patient/family, informal care, paid labour (productivity), non-paid opportunity costs, education, and consumption. Patient/family costs were captured in 11 studies and included patient time, travel expenses, out-of-pocket costs and premature burial costs. Informal caregiver support (non-family) and unpaid help by family/friends was captured in three studies. Paid labour losses were assessed in all but three studies. Three studies also captured the costs and inability to perform non-paid work. Educational costs and future non-health consumption costs were each captured in one study. The inclusion of intersectoral costs resulted in more favourable cost estimates.
CONCLUSIONS: This systematic review suggests that economic evaluations of interventions relating to STIs that adopt a societal perspective tend to be limited in scope. There is an urgent need for economic evaluations to be more comprehensive in order to allow policy/decision-makers to make better-informed decisions.

Keywords

References

  1. Health Policy. 2009 Dec;93(2-3):85-92 [PMID: 19709773]
  2. Cost Eff Resour Alloc. 2017 Sep 4;15:18 [PMID: 28878573]
  3. Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):705-721 [PMID: 27805466]
  4. PLoS One. 2020 Sep 30;15(9):e0239611 [PMID: 32997696]
  5. Pharmacoeconomics. 2013 Jul;31(7):537-49 [PMID: 23620213]
  6. Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):723-732 [PMID: 27762640]
  7. Clin Infect Dis. 2016 Dec 1;63(11):1495-1504 [PMID: 27558571]
  8. AIDS Behav. 2017 Mar;21(3):619-625 [PMID: 27624729]
  9. Int J Technol Assess Health Care. 2020 Apr;36(2):72-74 [PMID: 32000868]
  10. Am J Prev Med. 2016 Aug;51(2):216-224 [PMID: 26952078]
  11. Value Health. 2017 Apr;20(4):699-704 [PMID: 28408014]
  12. Sex Transm Infect. 2021 Aug;97(5):334-344 [PMID: 33653881]
  13. Lancet HIV. 2015 Sep;2(9):e393-400 [PMID: 26423553]
  14. Sex Transm Infect. 2015 Sep;91(6):423-9 [PMID: 25759475]
  15. Clin Ther. 2000 Nov;22(11):1333-45 [PMID: 11117658]
  16. Med Care. 2009 Jul;47(7 Suppl 1):S28-32 [PMID: 19536023]
  17. Value Health. 2021 Mar;24(3):431-442 [PMID: 33641778]
  18. Pharmacoeconomics. 2020 Oct;38(10):1135-1145 [PMID: 32696192]
  19. BMJ. 2009 Oct 08;339:b3884 [PMID: 19815582]
  20. Pharmacoeconomics. 2019 Feb;37(2):119-130 [PMID: 30474803]
  21. Cancer Epidemiol Biomarkers Prev. 2021 Jun;30(6):1114-1121 [PMID: 33771846]
  22. J Mark Access Health Policy. 2015 Aug 12;3: [PMID: 27123182]
  23. Health Econ Rev. 2014 Dec;4(1):15 [PMID: 26208918]
  24. PLoS One. 2013 Oct 18;8(10):e78548 [PMID: 24205255]
  25. Int J Technol Assess Health Care. 2021 Mar 09;37:e43 [PMID: 33686927]
  26. Vaccine. 2009 Jul 30;27(35):4776-83 [PMID: 19539578]
  27. BMJ. 2008 Sep 29;337:a1204 [PMID: 18824485]
  28. J Natl Cancer Inst. 2009 Aug 5;101(15):1083-92 [PMID: 19571256]
  29. J Acquir Immune Defic Syndr. 2006 Dec 1;43(4):451-7 [PMID: 16980906]
  30. Hum Vaccin Immunother. 2014;10(12):3737-45 [PMID: 25483706]
  31. Emerg Infect Dis. 2015 Jun;21(6):960-8 [PMID: 25989525]
  32. Sex Transm Dis. 2006 Oct;33(10 Suppl):S117-21 [PMID: 17003678]
  33. Scand J Public Health. 2010 Mar;38(2):141-50 [PMID: 20064921]
  34. BMC Public Health. 2013 Oct 24;13:1001 [PMID: 24153037]
  35. Syst Rev. 2021 Mar 29;10(1):89 [PMID: 33781348]
  36. JAMA. 2016 Sep 13;316(10):1093-103 [PMID: 27623463]
  37. Sex Transm Infect. 2003 Oct;79(5):372-3 [PMID: 14573831]
  38. J Psychosom Res. 2019 Mar;118:34-40 [PMID: 30782352]
  39. J Med Libr Assoc. 2016 Jul;104(3):240-3 [PMID: 27366130]
  40. J Ment Health Policy Econ. 2013 Dec;16(4):179-86 [PMID: 24526586]
  41. BJOG. 2002 Jan;109(1):44-56 [PMID: 11843373]
  42. Can J Infect Dis Med Microbiol. 2015 Jan-Feb;26(1):23-9 [PMID: 25798150]
  43. Vaccine. 2009 Aug 13;27(37):5133-41 [PMID: 19567244]
  44. Clin Infect Dis. 2019 Feb 1;68(4):658-667 [PMID: 30239629]
  45. BMC Infect Dis. 2019 Dec 2;19(1):1019 [PMID: 31791253]
  46. AIDS Care. 2008 Apr;20(4):449-55 [PMID: 18449822]
  47. PLoS One. 2019 Oct 9;14(10):e0223658 [PMID: 31596899]
  48. Health Technol Assess. 2010 Feb;14(7):1-206, iii-iv [PMID: 20178696]
  49. Sex Transm Dis. 2011 Nov;38(11):1067-73 [PMID: 21992986]
  50. Eur J Health Econ. 2016 May;17(4):391-402 [PMID: 25876834]
  51. Sex Health. 2013 Nov;10(5):434-7 [PMID: 23987746]
  52. Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):689-704 [PMID: 27805469]
  53. BMC Public Health. 2020 Feb 27;20(1):271 [PMID: 32103750]
  54. Vaccine. 2009 Aug 13;27(37):5111-9 [PMID: 19567242]
  55. Sex Transm Infect. 2021 Dec;97(8):607-612 [PMID: 33431605]
  56. Ann Intern Med. 2009 Oct 20;151(8):538-45 [PMID: 19841455]
  57. Sex Transm Infect. 2007 Oct;83(6):423-4 [PMID: 17911139]
  58. Pathog Glob Health. 2016 Oct - Dec;110(7-8):292-302 [PMID: 27958189]
  59. Vaccine. 2018 Aug 16;36(34):5160-5165 [PMID: 30017146]
  60. Value Health. 2019 Feb;22(2):194-202 [PMID: 30711064]

MeSH Term

Humans
Cost-Benefit Analysis
Patient Care
Efficiency
Delivery of Health Care
Sexually Transmitted Diseases

Word Cloud

Created with Highcharts 10.0.0costsSTIseconomicstudiesevaluationsperspectiveintersectoralinfectionsstudyreviewincludedcapturedtransmittedsectorsectorsielabourinterventionsrelatingsocietalSexuallyimpactalsoeducationaimedhealthcaretermsevaluationconsideredassessedIntersectoralcostpatient/familyproductivitynarrativesynthesispayernon-paidconsumptionthreesystematicBACKGROUND/OBJECTIVE:healthprivateresourcesaffectedfamiliessocietyidentifyincludeiianalysebroaderiiicategoriseivassessoverallresultsMETHODS:Sevendatabasessearched:MEDLINEPubMedEMBASEOvidWebScienceCINAHLPsycINFOEconLitNHSEEDKeysearchspecifictrial-model-basedconductedOECDmembercountryStudiesextractedcategorisedusingDrummond'sclassificationschemeperformedRESULTS:Twenty-ninequalifieddataextractionTwenty-eightapplied8additionallyadoptedOneusedmodifiedfollowingidentified:informalcarepaidopportunityPatient/family11patienttimetravelexpensesout-of-pocketprematureburialInformalcaregiversupportnon-familyunpaidhelpfamily/friendsPaidlossesThreeinabilityperformworkEducationalfuturenon-healthoneinclusionresultedfavourableestimatesCONCLUSIONS:suggestsadopttendlimitedscopeurgentneedcomprehensiveorderallowpolicy/decision-makersmakebetter-informeddecisionssexually?CostsEconomicHIVHTAHealtheconomicsMultisectoralSocietal

Similar Articles

Cited By